New schizophrenia drug shows promise in Long-Term trial
NCT ID NCT01625897
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tested the long-term safety and effectiveness of a drug called MP-214 in 125 people with chronic schizophrenia or elderly patients aged 65-74. The main goal was to see how many participants had side effects. The study is complete, but results are not yet published.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Aizu-Wakamatsu, Fukushima, Japan
Conditions
Explore the condition pages connected to this study.